Alnylam Pharmaceuticals (ALNY) Free Cash Flow Growth (1y) (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) Free Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 137.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 137.65% |
| Dec 31, 2025 | 210.32% |
| Sep 30, 2025 | 1,629.56% |
| Jun 30, 2025 | 12.84% |
| Mar 31, 2025 | -54.35% |
| Dec 31, 2024 | -880.00% |
| Sep 30, 2024 | -94.28% |
| Jun 30, 2024 | 267.33% |
| Mar 31, 2024 | 53.56% |
| Dec 31, 2023 | 106.72% |
| Sep 30, 2023 | 491.11% |
| Jun 30, 2023 | 46.06% |
| Mar 31, 2023 | 4.59% |
| Dec 31, 2022 | -81.12% |
| Sep 30, 2022 | 45.33% |
| Jun 30, 2022 | 2.88% |
| Mar 31, 2022 | 22.18% |
| Dec 31, 2021 | -22.80% |
| Sep 30, 2021 | -30.43% |
| Jun 30, 2021 | 13.33% |